Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's morning trading, 87 companies set new 52-week lows.
18 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on Monday. Kaival Brands Innovations recently announced plans to launch distribution of its products in the U.K.
Celsion Reports Will Give Oral Presentation At Int’l. Vaccine Congress Monday, Oct. 18 At 7:30 a.m. EDT
Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that a time of Monday, October 18, 2021 at 7:30 a.m. Eastern
Celsion Corporation Announces Oral Presentation At International Vaccines Congress
Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA mediated immunotherapy and next-generation nucleic vaccines, announces that Khursheed Anwer, Ph.D., executive vice president and
CLSN: Initiating Coverage of Celsion Corporation; Novel DNA-Based Cancer Immunotherapy Technology…
By David Bautz, PhD
NASDAQ:CLSN
READ THE FULL CLSN RESEARCH REPORT
Celsion Shares Spike To Session High Near $1, Up 9.5% As Traders Circulate Zack’s Small Cap Research Note Showing Initiation Of Stock With $3.50 Price Target
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_10112021_CLSN_Bautz.pdf
Celsion GmbH Announces Publication Of Article Reviewing History Of ThermoDox Drug Development In Advanced Drug Delivery Reviews
Celsion GmbH, a wholly owned subsidiary of Celsion Corporation (NASDAQ: CLSN), a clinical-stage biotechnology company focused on DNA-based immunotherapy and next-generation vaccines, announces the
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers
Protagonist Therapeutics (NASDAQ:PTGX) shares moved upwards by 89.3% to $34.53 during Monday's pre-market session. The market value of their outstanding shares is at $1.6 billion.
Celsion Corporation Announces New Management Appointments
Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion